IDiyas

For the Inventor, By the Inventor

Rome, Italy

Fabio Giannessi

USPTO Granted Patents = 21


Average Co-Inventor Count = 4.6

ph-index = 5

Forward Citations = 119(Granted Patents)


Location History:

  • Pomezia, IT (2001 - 2008)
  • Rome, IT (1991 - 2010)

Company Filing History:

goldMedal21 out of 343 
 
Sigma-tau Industrie Farmaceutiche Riunite S.p.a.
 patents

Years Active: 1991-2010

Loading Chart...
Loading Chart...
21 patents (USPTO):Explore Patents
1. RE41226 - Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase (2010-04-12),
2. RE40861 - Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase (2009-07-20),
3. 7375124 - Use of α-phenylthiocarboxylic and α-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity (2008-05-20),
4. 7368605 - Variously substituted derivatives of guanidine, and their use as medicines with anti-diabetes and/or anti-obesity activity (2008-05-06),
5. 6822115 - Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid (2004-11-23),
6. 6528684 - Synthesis of (R) and (S) -aminocarnitine and their derivatives starting from D- and L-aspartic acid (2003-03-04),
7. 6444701 - Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase (2002-09-03),
8. 6369073 - Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase (2002-04-09),
9. 6316667 - Process for the preparation of R-(-)-carnitine (2001-11-13),
10. 6127552 - Process for producing (R)-3-hydroxy-4-butyrolactone useful for preparing (2000-10-03),
11. 5714619 - Process for the preparation of (S)-.beta.-hydroxy-.gamma.-butyrolactone (1998-02-03),
12. 5599978 - Process for manufacturing L-(-)-carnitine from a waste product having (1997-02-04),
13. 5532410 - Process for manufacturing L(-)-carnitine from a waste product having (1996-07-02),
14. 5532409 - Process for producing R-aminocarnitine and S-aminocarnitine (1996-07-02),
15. 5491260 - Process for manufacturing L-(-)-carnitine from derivatives having a (1996-02-13),

Title: Innovations of Fabio Giannessi in Pharmaceutical Patents

Introduction: Fabio Giannessi, an accomplished inventor based in Rome, Italy, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 21 patents, Giannessi is particularly noted for his work on compounds that exhibit reversible inhibiting activity of carnitine palmitoyl-transferase. His research has the potential to impact various medical conditions, including hyperglycemia and heart diseases.

Latest Patents: Among his latest patents, Giannessi has focused on compounds of formula (I), which have displayed reversible inhibiting activity of carnitine palmitoyl-transferase. These compounds are poised to be instrumental in developing medicaments aimed at treating diseases associated with the hyperactivity of this enzyme, such as diabetes, heart failure, and ischemia.

Career Highlights: Currently, Fabio Giannessi is affiliated with Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., a prominent company in the pharmaceutical industry. His work is characterized by a commitment to research and innovation in creating effective drug formulations that cater to unmet medical needs.

Collaborations: Giannessi has worked alongside esteemed colleagues, including Maria Ornella Tinti and Francesco De Angelis. Their joint efforts represent a collaborative approach in advancing pharmaceutical science and developing solutions for complex health challenges.

Conclusion: Fabio Giannessi stands out as a notable inventor in the pharmaceutical sector, with a focus on improving medical therapies through innovative compounds. His ongoing research and patent contributions are crucial for the advancement of treatments that target serious health issues, benefiting countless patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…